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ABSTRACT
Inhaled corticosteroid (ICS) therapy is a mainstay of bronchial asthma management. Many clinical studies have
indicated that an early start with higher doses of ICS contributes to a better prognosis for asthmatic patients,
with improved pulmonary functions, airway hyperresponsiveness and quality of life. The current asthma guide-
lines suggest that once control is achieved, the dose of ICS should be reduced (stepped down) to the minimal
level required to control the disease. The rationale for stepping down the dose includes : 1) minimizing adverse
effects, 2) contributing to a precise determination of disease severity and 3) achieving better compliance with
the therapeutic regimen. However, a one-time reduction in the ICS dose of over 50% results in a high exacer-
bation rate (50―78%), and predictive markers for the step-down have not yet been established. Leukotriene re-
ceptor antagonist (LTRA) or inhaled long acting β2-stimulant (LABA) have led to successful step-down among
patients who require a high dose of ICS to control their condition. When asthma becomes less controllable and
thus requires a step-up of therapy, adding LTRA, LABA or theophylline (still a good choice in terms of cost ef-
fectiveness) results in better control than doubling the dose of ICS. However, stepwise management is mainly
applied to patients with mild to moderate asthma. Severe asthma pathophysiologically differs from mild to mod-
erate asthma and problems in applying stepwise management remain unresolved. Thus, efforts must be tar-
geted towards developing more effective therapeutic strategies with which to manage all types of asthma．
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INTRODUCTION
Many guidelines for the management of bronchial
asthma1-3 classify severity based on clinical and symp-
tomatic indices as intermittent (step 1), mild persis-
tent (step 2), moderate persistent (step 3) and severe
persistent (step 4). Furthermore, for long-term man-
agement of asthma , the guidelines recommend a
daily medication regimen corresponding to severity.
Most guidelines suggest a step-up strategy, starting
with a low dose that is progressively increased until
asthma is controlled. However, recent guidelines2-4
indicate a step-down strategy that starts with 800 μg
or more of inhaled corticosteroids (ICS) per day even
for mild asthmatics, and reduction of the dose after
control is achieved. In addition to ICS, doses of sus-
tained release theophylline, β2 stimulants and other
anti-asthmatic agents , may also be modified in the
“step-up” or “step-down” approach to asthma manage-
ment．
The ultimate goals in asthma treatment are to avoid
mortality and to improve the quality of life (QOL) by
minimizing side effects. However, whether the step-
up or the step-down approach is more effective in
achieving these goals remains obscure. During prac-
tical applications of the step-down approach, how the
dose of medication is reduced and whether optimal
clinical indices other than pulmonary functions and
clinical symptoms can determine the indication and
predict the prognosis of the procedure remain ob-
scure．
The present paper reviews published studies that
have examined the issues described above, and then
offers some opinions regarding the long-term step-
wise management of bronchial asthma．
STEP-UP OR STEP-DOWN ?
The 1997 NIH guidelines2 included a novel way to
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Fig. 1 NIH guidelines2 ofer two approaches for gaining 
asthma control. (1) Start with high-dose therapy and step-
down and (2) gradualy step-up therapy.  (Figure quoted 
from NIH guideline2)
Two Approaches to Gaining Control of Asthma:
(1) Start with High-dose Therapy and Step down
(2) Gradually Step up Therapy
STEP 4
STEP 3
STEP 2
STEP 1
(1)
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start managing asthma. Figure 1 shows that the start-
ing dosage corresponds to that for moderate or se-
vere asthma, regardless of the degree of disease se-
verity . The guidelines proposed that this strategy
would lead to a better prognosis than that achieved
with a starting dosage that corresponded to the sever-
ity. This was based on a three-year clinical study of
childhood asthma conducted by Haahtela et al.5 This
study found that airway hyperresponsiveness was
more improved by the early inhalation of a sufficient
dosage of budesonide rather than two years later, and
that persistent control of mild asthma could be fol-
lowed by a reduced dose as a maintenance therapy.
Pauwels et al. recently reported that early interven-
tion with low dose budesonide in children with mild
persistent asthma decreased the risk of severe exac-
erbation and improved asthma control.6
Campbell7 described a strategy initially consisting
of 800 μgday of inhaled budesonide for 6 weeks fol-
lowed by 400 μgday for 12 weeks for adults with
mild to moderate adult asthma. They found that peak
expiratory flow rate (PEF) was more improved and
that rescue use of an inhaled β2-stimulant was less
frequent, compared with the 400 μgday of budeson-
ide for 18 weeks. One report indicates that improved
airway hyperresponsiveness in mild to moderate
asthmatics depends on the initial dose of inhaled
budesonide.8 Another clinical study9 of starting ther-
apy with a high dose of ICS including oral predniso-
lone revealed a better prognosis after 8 months as
well as in the short term, compared with patients
treated with the standard dosage. However, a recent
study10 of mild asthmatics did not identify any differ-
ence in pulmonary functions at the end of 13 weeks
during which a strategy that included high initial
dose of ICS followed by a low dose was compared
with that starting with a low dose.
From the reports mentioned above, it is indicated
that starting therapy with ICS as soon as possible is
essential in the management of bronchial asthma .
Since the early start of asthma therapy is prerequi-
site, the author considers that for mild to moderate
asthma, the dose of ICS should correspond to step 3
or more, and then the dose could be stepped down af-
ter verifying control for at least 3 months. This inter-
val is recommended in the NIH and WHO guidelines.
This method should result in more improved symp-
toms, pulmonary functions and hyperresponsiveness
compared with the step-up method．
STEP-DOWN IN INHALED CORTICOSTER-
OID THERAPY
The current asthma guidelines suggest that once con-
trol is achieved, the amount of controller therapy, es-
pecially the dose of ICS should be minimized to main-
tain disease control. At least three rationales should
be considered for the step-down. Firstly, adverse ef-
fects of medications must be minimized. Since ICS is
compounded with propionate, the liver was thought
to inactivate it, thus generating very few systemic ad-
verse effects. However, the meta-analysis of reported
studies of ICS side effects by Lipworth11 indicated
that inhaled fluticasone propionate dose-dependently
suppressed early morning urinary and blood cortisol
levels to a similar extent to that induced by oral pred-
nisolone. Other types of ICS also dose-dependently
suppress cortisol levels, although not to the extent of
oral prednisolone . Thus , inhaled corticosteroid ,
which is a mainstay of asthma treatment , must be
prescribed with considerations as to the possibility of
side effects. Secondly, step-down might contribute to
the precise determination of disease severity . No
guidelines can account for individual differences in
drug response . One patient with some severity
(based on symptom frequency and pulmonary func-
tions) might respond favorably to a low-dose inhaled
corticosteroid , whereas another with the same de-
gree of severity might not . By stepping down the
asthma therapy, valuable information can be obtained
about individual responses to the medication, result-
ing in a precise determination of disease severity .
Thirdly, step-down might lead to better compliance
with the drug regimen．
Many clinical studies have addressed ICS step
down from various perspectives , for example , the
long-term clinical course after the step-down,12,13 pre-
dictive markers for successful step down14-19 and add-
on medication that enables successful step-
down.13,20-23 The dose of ICS was reduced by 50% at
one time in many of these clinical studies. This re-
sulted in exacerbation rates after step-down of over
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Fig. 2 Changes in inhaled beclomethasone dipropionate (iBDP) doses during 2-year fol-
low up study in mild to moderate asthmatics after ICS step-down. During this period, we 
evaluated symptoms and pulmonary functions every 3 months.  Dosage of iBDP was de-
creased by 1/3-1/4 or increased 1.5-2-fold depending upon clinical condition of asthma.  
Patients assigned according to pre-study serum levels of eosinophil cationic protein (ECP). 
Group A (●), sECP ＜25 μg/l (n=13); group B(■), sECP ≧25 μg/l (n=11); group C(□), 
sECP≧ 25μg/l under pranlukast or seratrodast administration (n=11).  At end of study, 
iBDP dose is around 400―700 μg/day in al groups (doted circle), although that in group C 
tends to be lower than that in other groups (Quoted and modified from Baba et al.13).
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Time after the initial step down in iBDP therapy (months)
50% (50 to 78%)14,16,17,19 although one study reported
a rate of 31%.12 Guidelines 1,2 recommend reducing
the dose of inhaled corticosteroid by 25% every 2 to 3
months as long as asthma is controlled well. The re-
sults of other step-down studies indicate that this rec-
ommendation is reasonable, despite the absence of
concrete clinical evidence．
The literature indicates that sputum eosinophil
counts,16,17,19 airway hyperresponsiveness,17-19 serum
level of eosinophil cationic protein (ECP)14,15 and ex-
haled nitric oxide19 can be markers of successful ICS
step-down. However, these markers have not been
established as practical standard parameters．
The extent of the reduction in ICS dose must be
considered. We observed the two-year clinical course
of mild to moderate asthmatics after step-down in-
haled corticosteroid therapy and evaluated symptoms
and pulmonary functions every 3 months.13 We de-
creased or increased the dose of inhaled beclometha-
sone dipropionate (BDP) by 13−14 or by 1.5−2-fold,
respectively , according to clinical severity . The re-
sults showed that the dose of BDP required to main-
tain control of asthma was around 400―700 μgday at
the end of the study period (24 months)(Fig. 2).13
Thus, approximately 400 μgday of BDP is the mini-
mal dose required to maintain good control of mild to
moderate asthma and aggressive dose reduction
might not be appropriate even when the severity of
the asthma during treatment is intermittent.
We would also like to review the add-on medication
to ICS that leads to successful step-down. Some adult
asthmatics require single doses above 1000 μgday of
ICS to control symptoms . Leukotriene antagonists
(LTRA) lead to successful step-down of inhaled corti-
costeroid for such patients . 20-22 We also confirmed
that LTRA or thromboxane A2 antagonists can bring
about successful dose reduction to around 600 μg
day of BDP in such patients (Fig. 2 ).12 Inhaled long-
acting β2-stimulants (LABA) have recently attracted
interest in terms of enabling the step-down of inhaled
corticosteroid.23,24 However, LTRA or LABA cannot
totally substitute for ICS therapy.23-25
THEOPHYLLINE
Theophylline is a bronchodilator, but it also has anti-
inflammatory effects,26,27 which might make it suit-
able for managing COPD. Other reports have also in-
dicated that theophylline has potential as an add-on
agent to ICS therapy in long-term asthma manage-
ment.28-30
Theophylline maintains a key position in asthma
therapy because of good cost effectiveness . 1 How-
ever, theophylline has a narrow concentration range
that is clinically safe and effective (5 to 20 μgml).
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Thus, the blood concentration of theophylline must
be monitored. We reported that the V25HT value
which reflects airflow in the peripheral airway, de-
creased after theophylline withdrawal in many mild to
moderate asthmatics who were controlled by both in-
haled corticosteroid and theophylline.31 In addition,
we found that the values of computer-simulated blood
concentration of theophylline tended to be higher in
the exacerbated, than in the stabilized group and be-
fore than after withdrawal. The results of that study
indicated that computer-simulated blood concentra-
tion might be a useful parameter in determining indi-
cations for theophylline step-down．
The blood concentration of theophylline varies due
to dosing schedules, smoking habit, age and other
drugs. A single nucleotide polymorphism (SNP) for
CYP1A2, which is an enzyme that metabolizes theo-
phylline , might be another factor influencing theo-
phylline activity in asthmatics.32 We are presently in-
vestigating the relationship between the SNP of
CYP1A2 and the computer-simulated blood concen-
tration of a given theophylline dose in 27 adult asth-
matics . The results obtained to date are similar to
those of the previous studies (data not shown). Thus,
an indication for theophylline administration or step-
ping down the dose and cautioning for adverse ef-
fects might be possible from analyzing the SNP on
CYP1A2. This would subsequently lead to a more fa-
vorable stepwise management of bronchial asthma．
STEP-UP OF THERAPY
In addition to theophylline, LTRA or LABA is a useful
add-on agent to ICS.33-35 The principle of clinical stud-
ies regarding“add-on” medication is that either
LTRA, LABA or theophylline improves lung function
more than doubling the dose of ICS. Furthermore, in-
haled salmeterol xinafoate , an LABA, brings about
better improvement of pulmonary functions than
Montelukast, an LTRA.36
The clinical effect of anti-asthmatic drugs is evalu-
ated by other means in addition to pulmonary func-
tion. Daily symptoms such as the extent of dyspnea,
daily activity and frequency of symptoms are also im-
portant clinical parameters. In fact, LTRA improves
these parameters as much as LABA . 37 Therefore ,
which drug is the most appropriate as an add-on
agent to ICS cannot be easily determined. As LTRA
has been reported to inhibit remodeling especially re-
lated to smooth muscle hyperplasia and as theophyl-
line has been recognized as an anti-inflammatory
agent, a new look at extant drugs might be justified,
to allow precise selection from them in asthma man-
agement. Whether the simultaneous administration
of, for example, both LTRA and LABA added to ICS is
more effective than either LTRA or LABA alone espe-
cially in severe persistent asthma, remains undeter-
mined．
The β2-stimulants are mainly applied as inhalation
therapies in Europe and in the USA. In Japan, β2-
stimulants have historically been applied as oral anti-
asthmatic drugs . Nevertheless , little evidence sup-
ports the clinical usefulness of oral β2-stimulant as an
add-on agent to ICS. We are currently administering
the oral β2-stimulant , procaterol hydrochloride , to
adult asthmatics whose disease was not controlled
with 400 μgday of inhaled fluticasone. The data tend
to show that QOL and daily variability of PEF are im-
proved. Whether oral β2-stimulants have long-term
clinical benefits for asthma management also remains
unresolved．
CONCLUSION
Because of widespread ICS therapy, the QOL of asth-
matics has remarkably improved. However, the early
administration of the appropriate dose of corticoster-
oids is essential to achieve such effects. Early inter-
vention must be accepted as a key concept in asthma
management.
On the other hand , long-term compliance is re-
quired and adverse drug effects must be avoided .
Most bronchial asthmatics have mild to moderate
symptoms. Although the side effects of inhaled corti-
costeroid are slight, they sometimes affect the QOL.
Therefore, if asthmatic symptoms are well controlled
in principle, then therapy, especially that of inhaled
corticosteroid should be stepped down. The choice of
step-up or -down requires an accurate evaluation of
asthma severity, and this can be achieved through ap-
propriate treatment. Thus, after early induction of the
therapy, long-term management with a dose exactly
corresponding to disease severity might result in
good compliance, avoidance of adverse effects and
good control．
The present review focused on treatment for mild
to moderate asthma, where control is achievable but
requires consideration of several points . However ,
asthma management is still associated with several
problems such as education, psychological and psy-
chiatric care. In severe asthmatics in whom neutro-
phils are more concerned with the pathophysiology
than with that of mild to moderate asthma,38-40 step-
ping down the treatment is often very difficult and
would require other considerations . The optimal
treatment for asthma might be realized only when dif-
ferent types of strategies are systematically com-
bined.
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